title: Canadian Consensus Conference on osteoporosis, 2006 update.
abstract: OBJECTIVE
  To provide guidelines for the health care provider on the diagnosis and clinical management of postmenopausal osteoporosis.
  
  
  RESULTS
  Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis.
  
  
  METHODS
  MEDLINE and the Cochrane database were searched for articles in English on subjects related to osteoporosis diagnosis, prevention, and management from March 2001 to April 2005. The authors critically reviewed the evidence and developed the recommendations according to the Journal of Obstetrics and Gynaecology Canada's methodology and consensus development process.
  
  
  METHODS
  The quality of evidence is rated using the criteria described in the report of the Canadian Task Force on the Periodic Health Examination. Recommendations for practice are ranked according to the method described in this report.
  
  
  BACKGROUND
  The development of this consensus guideline was supported by unrestricted educational grants from Berlex Canada Inc., Lilly Canada, Merck Frosst, Novartis, Novogen, Novo Nordisk, Proctor and Gamble, Schering Canada, and Wyeth Canada.
authors.affiliation: Quebec QC.
authors.forename: Jacques P
authors.initials: JP
authors.lastname: Brown
authors.forename: Michel
authors.initials: M
authors.lastname: Fortier
authors.forename: Heather
authors.initials: H
authors.lastname: Frame
authors.forename: André
authors.initials: A
authors.lastname: Lalonde
authors.forename: Alexandra
authors.initials: A
authors.lastname: Papaioannou
authors.forename: Vyta
authors.initials: V
authors.lastname: Senikas
authors.forename: Chui Kin
authors.initials: CK
authors.lastname: Yuen
mesh_terms: D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*; D058866:Osteoporotic Fractures / Q000209:etiology / Q000517:prevention & control